Global mortality of chronic liver diseases attributable to Hepatitis B virus and Hepatitis C virus infections from 1990 to 2019 and projections to 2030.

Autor:	Ou TY; Division of Infectious Diseases, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. Electronic address: 93023@w.tmu.edu.tw., Huy LD; College of Health Sciences, VinUniversity, Hanoi, Viet Nam. Electronic address: duchuya2@gmail.com., Mayne J; College of Health Sciences, VinUniversity, Hanoi, Viet Nam; Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: jeffrey.m@vinuni.edu.vn., Shih CL; National Health Insurance Administration, Ministry of Health and Welfare, Taipei, Taiwan. Electronic address: md01@mohw.gov.tw., Mai Xuan H; The Master Program in Smart Healthcare Management, International College of Sustainability Innovations, National Taipei University, New Taipei, Taiwan. Electronic address: xuanhaomai.95@gmail.com., Thi Hong Nguyen N; Health Personnel Training Institute, University of Medicine and Pharmacy, Hue University, Hue city, Viet Nam; School of Nutrition and Health Sciences, Taipei Medical University, Taipei, Taiwan. Electronic address: nthnhi@hueuni.edu.vn., Nguyen Hoai L; Nutrition Department, Hue Central Hospital, Hue city, Viet Nam. Electronic address: linh.nguyenhoai5@gmail.com., Thi My Bui L; Faculty of Public Health, Da Nang University of Medical Technology and Pharmacy, Da Nang, Viet Nam. Electronic address: mylinhbui147@gmail.com., Chang YM; School of Health Care Administration, College of Management, Taipei Medical University, Taipei, Taiwan; Research Center of Health and Welfare Policy, Taipei Medical University, Taipei, Taiwan. Electronic address: cjym@tmu.edu.tw., Abdi AA; School of Health Care Administration, College of Management, Taipei Medical University, Taipei, Taiwan; Hargeisa Group of Hospitals, Somaliland. Electronic address: Kijandhe2@gmail.com., Hsu SC; Department of Emergency, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; Emergency Department, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. Electronic address: 1980bradhsu@gmail.com., Lin HJ; Department of Emergency, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; Department of Emergency Medicine, Chi Mei Medical Center, Tainan, Taiwan. Electronic address: 790001@mail.chimei.org.tw., Huang CC; School of Health Care Administration, College of Management, Taipei Medical University, Taipei, Taiwan; Department of Accounting, School of Business, Soochow University, Taipei, Taiwan; International Ph.D. Program in Biotech and Healthcare Management, College of Management, Taipei Medical University, Taipei, Taiwan; School of Gerontology and Long-Term Care, College of Nursing, Taipei Medical University, Taipei, Taiwan; School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan. Electronic address: cc.lab.886@gmail.com.
Jazyk:	angličtina
Zdroj:	Journal of infection and public health [J Infect Public Health] 2024 Jul; Vol. 17 (7), pp. 102443. Date of Electronic Publication: 2024 May 08.
DOI:	10.1016/j.jiph.2024.04.027
Abstrakt:	Background: The burden of chronic liver disease (CLD) deaths attributable to the hepatitis B virus (HBV) and hepatitis C virus (HCV) remains unknown. Further research is required to elucidate the extent of this burden in the eventual elimination of these diseases. Methods: Data on liver cancer, cirrhosis, and other CLD among 204 countries and territories between 1990 and 2019 was extracted from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) published in 2019. The Bayesian age-period-cohort model was used to analyze the temporal trend and predict the disease burden by 2030. Results: The number of HCV-related CLD deaths surpassed that of CLD deaths caused by HBV in 2019 (536833 deaths versus 523003 deaths) and is expected to be maintained until 2030 (689124 deaths versus 628824 deaths). East Asia had the highest burden of chronic HBV and HCV infections during the study period. In 2019, the largest age-standardized death rates (ASDR) of CLD deaths caused by HBV and HCV were mainly observed in Western Sub-Saharan Africa (18.75%) and Eastern Sub-Saharan Africa (16.42%), respectively. South Asia and East Asia are predicted to have the highest number of CLD deaths related to HCV and HBV by 2030. Eastern Europe and South Asia show the largest expected increase in disease burden caused by HCV or HBV between 2019 and 2030. No GBD region is projected to achieve the WHO target of a 65% reduction in mortality from chronic HBV and HCV infections by 2030. Conclusions: Although the mortality of CLD caused by HBV and HCV decreased in the last three decades (from 1990 to 2019), the number of deaths will continue to increase until 2030. Therefore, governments and international organizations need to strengthen the effectiveness of vaccines, screening, and treatment, especially in potential emerging hotspot regions. Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu